Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827722 | 0.86 | MAPT (0.34) | NPC1MAPT | |
| SCHEMBL13722629 | 0.85 | NPC1 (0.36) | NPC1MAPTKLKB1 | |
| SCHEMBL14151228 | 0.81 | NPC1 (0.34) | NPC1MAPT | |
| SCHEMBL16330986 | 0.76 | NPC1 (0.34) | NPC1MAPTKLKB1 | |
| SCHEMBL14152167 | 0.75 | NPC1 (0.34) | NPC1 | |
| SCHEMBL30889616 | 0.73 | NPC1 (0.36) | NPC1MAPTKLKB1 | |
| SCHEMBL14151439 | 0.73 | NPC1 (0.36) | NPC1MAPT | |
| SCHEMBL5952355 | 0.73 | MAPT (0.40) | NPC1MAPT | |
| SCHEMBL30889427 | 0.71 | NPC1 (0.34) | NPC1MAPTKLKB1 | |
| SCHEMBL5953265 | 0.71 | KDM4E (0.55) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2537831-B1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-12-03 | — | — | EP | disclosed |
| EP-2537831-B1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| EP-2537831-A1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316170-A1 | Imidazole Derivative | S1PR2, S1PR1, SPHK2 | NPC1 149/4885MAPT 4228/4885KLKB1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.